当前位置：
X-MOL 学术
›
Mol. Cancer Ther.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Correction: In Vitro and In Vivo Synergistic Antitumor Activity of the Combination of BKM120 and Erlotinib in Head and Neck Cancer: Mechanism of Apoptosis and Resistance.
Molecular Cancer Therapeutics ( IF 5.3 ) Pub Date : 2020-09-01 , DOI: 10.1158/1535-7163.mct-20-0602 Abu Syed Md Anisuzzaman , Abedul Haque , Dongsheng Wang , Mohammad Aminur Rahman , Chao Zhang , Zhengjia Chen , Zhuo Georgia Chen , Dong M. Shin , A.R.M. Ruhul Amin
Molecular Cancer Therapeutics ( IF 5.3 ) Pub Date : 2020-09-01 , DOI: 10.1158/1535-7163.mct-20-0602 Abu Syed Md Anisuzzaman , Abedul Haque , Dongsheng Wang , Mohammad Aminur Rahman , Chao Zhang , Zhengjia Chen , Zhuo Georgia Chen , Dong M. Shin , A.R.M. Ruhul Amin
In the original version of [this article][1] ([1][2]), an IHC image (expression of p-EGFR control) was mistakenly used twice in Fig. 3B. The appropriate BKM panel in the p-EGFR column has replaced the duplicated panel. The error has been corrected in the latest online HTML and PDF versions of the
中文翻译：
校正：BKM120和厄洛替尼联合在头颈癌中的体外和体内协同抗肿瘤活性：细胞凋亡和耐药性机制。
在[本文] [1]（[1] [2]）的原始版本中，图3B中两次错误地使用了IHC图像（p-EGFR对照表达）。p-EGFR列中的适当BKM面板已替换了重复的面板。该错误已在最新的在线HTML和PDF版本的
更新日期：2020-09-02
中文翻译：
校正：BKM120和厄洛替尼联合在头颈癌中的体外和体内协同抗肿瘤活性：细胞凋亡和耐药性机制。
在[本文] [1]（[1] [2]）的原始版本中，图3B中两次错误地使用了IHC图像（p-EGFR对照表达）。p-EGFR列中的适当BKM面板已替换了重复的面板。该错误已在最新的在线HTML和PDF版本的
京公网安备 11010802027423号